PerkinElmer Announces Financial Results for the First Quarter of 2021
PerkinElmer (NYSE: PKI) reported strong Q1 2021 results with GAAP earnings per share of $3.37, up from $0.30 in Q1 2020, and revenues of $1.308 billion, a significant increase from $652 million year-over-year. The operating income was $468 million, reflecting a profit margin of 35.8%. Diagnostics revenue soared 236% to $853 million. The company raised its 2021 revenue guidance to $4.37 billion, and EPS forecast to $7.77 for the year.
- GAAP revenue increased 100% year-over-year to $1.308 billion.
- GAAP earnings per share rose to $3.37 from $0.30 in Q1 2020.
- Diagnostics segment revenue surged 236% to $853 million.
- None.
PerkinElmer, Inc. (NYSE: PKI), a global leader committed to innovating for a healthier world, today reported financial results for the first quarter ended April 4, 2021.
The Company reported GAAP earnings per share from continuing operations of
Adjusted earnings per share from continuing operations for the quarter was
Adjustments for the Company's non-GAAP financial measures have been noted in the attached reconciliations.
“The first quarter performance reinforces that PerkinElmer is emerging from COVID as a stronger organization top-to-bottom,” said Prahlad Singh, president and chief executive officer of PerkinElmer. “Our additional investments in innovation, commercial excellence, and people in 2020 are taking hold and give us increased confidence that we are well positioned to deliver faster growth in both the short and long-term.”
Financial Overview by Reporting Segment for the First Quarter
Discovery & Analytical Solutions
-
First quarter 2021 revenue was
$455 million , as compared to$398 million for the first quarter of 2020. Reported revenue increased14% and organic revenue increased6% as compared to the first quarter of 2020. -
First quarter 2021 operating income from continuing operations was
$43 million , as compared to$29 million for the comparable prior period. -
First quarter 2021 adjusted operating income was
$76 million , as compared to$54 million for the first quarter of 2020.
Diagnostics
-
First quarter 2021 revenue was
$853 million , as compared to$254 million for the first quarter of 2020. Reported revenue increased236% and organic revenue increased227% as compared to the first quarter of 2020. -
First quarter 2021 operating income from continuing operations was
$441 million , as compared to$30 million for the comparable prior period. -
First quarter 2021 adjusted operating income was
$483 million , as compared to$59 million for the first quarter of 2020.
Initiates Second Quarter and Raises Full Year 2021 Guidance
For the second quarter of 2021, the Company forecasts GAAP revenue of approximately
For the full year of 2021, the Company now forecasts GAAP revenue of
Conference Call Information
The Company will discuss its first quarter 2021 results and its outlook for business trends in a conference call on May 4, 2021 at 5:00 p.m. Eastern Time. To access the call, please dial (720) 405-2250 prior to the scheduled conference call time and provide the access code 7294952.
A live audio webcast of the call will be available on the Investors section of the Company’s website, www.perkinelmer.com. Please go to the site at least 15 minutes prior to the call in order to register, download, and install any necessary software. An archived version of the webcast will be posted on the Company’s website for a two-week period beginning approximately two hours after the call.
Use of Non-GAAP Financial Measures
In addition to financial measures prepared in accordance with generally accepted accounting principles (GAAP), this earnings announcement also contains non-GAAP financial measures. The reasons that we use these measures, a reconciliation of these measures to the most directly comparable GAAP measures, and other information relating to these measures are included below following our GAAP financial statements.
Factors Affecting Future Performance
This press release contains "forward-looking" statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements relating to estimates and projections of future earnings per share, cash flow and revenue growth and other financial results, developments relating to our customers and end-markets, and plans concerning business development opportunities, acquisitions and divestitures. Words such as "believes," "intends," "anticipates," "plans," "expects," "projects," "forecasts," "will" and similar expressions, and references to guidance, are intended to identify forward-looking statements. Such statements are based on management's current assumptions and expectations and no assurances can be given that our assumptions or expectations will prove to be correct. A number of important risk factors could cause actual results to differ materially from the results described, implied or projected in any forward-looking statements. These factors include, without limitation: (1) markets into which we sell our products declining or not growing as anticipated; (2) the effect of the COVID-19 pandemic on our sales and operations; (3) fluctuations in the global economic and political environments; (4) our failure to introduce new products in a timely manner; (5) our ability to execute acquisitions and license technologies, or to successfully integrate acquired businesses and licensed technologies into our existing business or to make them profitable, or successfully divest businesses; (6) our ability to compete effectively; (7) fluctuation in our quarterly operating results and our ability to adjust our operations to address unexpected changes; (8) significant disruption in third-party package delivery and import/export services or significant increases in prices for those services; (9) disruptions in the supply of raw materials and supplies; (10) our ability to retain key personnel; (11) significant di